
BioCardia, Inc. (NASDAQ:BCDA – Free Report) – Analysts at HC Wainwright raised their FY2026 EPS estimates for BioCardia in a research report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.63) per share for the year, up from their previous forecast of ($0.71). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.28) EPS.
BCDA has been the topic of a number of other research reports. Zacks Research raised BioCardia from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Wall Street Zen raised BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioCardia currently has an average rating of “Hold” and a consensus target price of $25.00.
BioCardia Stock Down 2.1%
Shares of NASDAQ:BCDA opened at $0.77 on Tuesday. The company has a market cap of $11.69 million, a P/E ratio of -1.48 and a beta of 0.69. BioCardia has a 52 week low of $0.66 and a 52 week high of $1.80. The company has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.05.
BioCardia (NASDAQ:BCDA – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01.
Institutional Investors Weigh In On BioCardia
A hedge fund recently raised its position in BioCardia stock. StoneX Group Inc. grew its stake in shares of BioCardia, Inc. (NASDAQ:BCDA – Free Report) by 67.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,445 shares of the company’s stock after purchasing an additional 13,425 shares during the period. StoneX Group Inc. owned approximately 0.22% of BioCardia worth $33,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.57% of the company’s stock.
About BioCardia
BioCardia, Inc. is a biotechnology company developing regenerative therapies for cardiovascular and pulmonary diseases. Its work centers on cell-based treatments intended to support the repair or function of damaged tissues. The company’s investigational programs include CardiAMP, an autologous cell therapy developed using a patient’s own bone marrow cells, and CardiALLO, an allogeneic therapy using donor cells. BioCardia also develops catheter-based systems, including its Helix device, to deliver biologic treatments to the heart.
Featured Articles
- Five stocks we like better than BioCardia
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
